Tiziana Life Sciences’ (TLSA) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Tiziana Life Sciences (NASDAQ:TLSA) in a report released on Tuesday,Benzinga reports.

Several other equities analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, August 26th. Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Tiziana Life Sciences presently has an average rating of “Hold”.

Tiziana Life Sciences Stock Performance

Shares of TLSA stock opened at $1.04 on Tuesday. Tiziana Life Sciences has a 1 year low of $0.76 and a 1 year high of $2.35. The stock’s 50 day simple moving average is $1.00 and its two-hundred day simple moving average is $1.19.

Insider Activity

In related news, CEO Ivor Elrifi bought 237,616 shares of the stock in a transaction dated Wednesday, August 5th. The stock was purchased at an average cost of $1.00 per share, with a total value of $237,616.00. Following the completion of the purchase, the chief executive officer owned 4,793,684 shares of the company’s stock, valued at $4,793,684. This trade represents a 5.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have acquired 988,423 shares of company stock worth $985,909 over the last ninety days. 39.82% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. bought a new position in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 323,240 shares of the company’s stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned 0.25% of Tiziana Life Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.